Omega Therapeutics IPO Presentation Deck

In vivo PoC in Complex Multi-genic Disease Program - ARDS Systemic administration of OEC candidate in lung-targeting LNP significantly decreased neutrophil infiltration in inflamed lung OEC candidate reduced infiltration of inflammatory mediators in lung (72h) 8x105. Neutrophils cells/mL BALF 6x105- 4x105- 2x105- 0 Normal Disease control OEC Dexamethasone Ⓒ2021 Omega Therapeutics, Inc. OEC candidate significantly different compared to disease control, Mann Whitney ● OEC candidate administration prior (-2h) to challenge and at peak of inflammation (8h) Significantly decreased neutrophil infiltration in bronchioalveolar lavage (BALF) at 72 hrs 26

View entire presentation